4D Molecular Therapeutics Inc

NASDAQ:FDMT   4:00:00 PM EDT
21.81
-1.36 (-5.87%)
6:08:53 PM EDT: $22.03 +0.22 (+1.01%)
Earnings Announcements

4D Molecular Therapeutics Reports Third Quarter 2022 Financial Results

Published: 11/09/2022 21:18 GMT
4D Molecular Therapeutics Inc (FDMT) - 4d Molecular Therapeutics Reports Third Quarter 2022 Financial Results.
Cash, Cash Equivalents and Marketable Securities Were $239 Million As of September 30, 2022.4d Molecular Therapeutics - Cash, Cash Equivalents and Marketable Securities Sufficient to Fund Operations Into the First Half of 2025.4d Molecular Therapeutics - Qtrly Net Loss per Share, Basic and Diluted $0.79.
Q4 Earnings per Share View $-0.80 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $3 Million
Adjusted EPS is expected to be -$0.80

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$1.03

More details on our Analysts Page.